drugset / Trial / NCT07809919
A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy Subjects
RandomizedSequentialTriple-blindOther
Summary
The purpose of this first-in-human study is to generate the necessary safety, tolerability, and pharmacokinetics (PK) information that will support further clinical development of LXE408 for the treatment of patients with visceral leishmaniasis and potentially Chagas disease.
Timeline
- Start
- 2018-12-21
- Primary completion
- 2021-09-27
- Completion
- 2021-09-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LXE408 | Small molecule | — | Oral |
| Background | Iohexol | Diagnostic / imaging agent | — | Intravenous |